The team turned to the SAMP8 mouse, a well-established model of accelerated aging that develops learning and memory deficits as early as four months of age and, from six months onward, begins to display neuropathological hallmarks reminiscent of Alzheimer’s disease. Within the hippocampus—the brain’s memory hub—these mice undergo a characteristic sequence: an early burst of neurogenic activity in the dentate gyrus, the region where new neurons are born, followed by depletion of the resident neural stem cell pool. That exhaustion, driven by signals within the local neurogenic niche, makes the SAMP8 an ideal testing ground for interventions meant to preserve or restore the birth of new neurons in adulthood.

The compound under scrutiny, known as ER272 or DPB, is a 12-deoxyphorbol diterpene originally isolated from plants of the Euphorbia genus. Unlike some of its chemical relatives, it does not promote tumors; instead, it activates classical protein kinase C isoforms by binding their C1B regulatory domain. Previous work had shown that ER272 triggers the release of TGF-α and exerts both neurogenic and neuroprotective effects, and that a two-month treatment ameliorated cognitive decline in six-month-old male SAMP8 mice. What remained unknown was whether females would respond at all—a question that matters, because most preclinical studies of hippocampal neurogenesis have been conducted in males alone, or in mixed cohorts never analyzed by sex.

To find out, the researchers gave four-month-old male and female SAMP8 mice daily intranasal doses of ER272 for eight consecutive weeks, delivering 18 microliters of a one-micromolar solution in alternating aliquots to each nostril. Age-matched SAMR1 mice, a strain that ages normally, served as controls. Throughout the treatment period, every animal received injections of BrdU, a synthetic nucleoside that incorporates into the DNA of dividing cells, allowing the team to tag and later count every neuron and glial cell born during the experiment. Behavioral testing—open field, new object discrimination, and the Morris water maze—took place during the final two weeks, with investigators blinded to treatment assignment.

The behavioral results were unambiguous. Both male and female SAMP8 mice showed impaired spatial learning in the water maze and severely compromised episodic memory in the new object discrimination task, particularly on the “what” and “when” components that test whether an animal remembers which object it saw and when. Yet only the males benefited from the drug. Treated males spent significantly more time in the target quadrant during the water maze retention probe and fully recovered their episodic memory performance. Treated females showed only a slight, statistically insignificant improvement, and direct comparisons confirmed that ER272-treated females performed significantly worse than treated males on the “what” and “when” paradigms. Open field testing ruled out changes in general locomotor activity as an explanation.

Underlying those divergent behavioral outcomes lay equally divergent cellular pictures. In male SAMP8 mice, the number of BrdU-labeled proliferating cells in the dentate gyrus dropped, and the population of newly generated immature neurons—cells positive for both BrdU and doublecortin—fell significantly, a loss that ER272 treatment fully prevented. In treated males, BrdU-positive cell counts even exceeded those of normal-aging controls and reached roughly double the levels seen in treated females. Female SAMP8 mice, by contrast, showed no significant reduction in newly generated immature neurons compared with female controls, and the drug produced only a modest, non-significant uptick. Notably, the proportion of dividing cells that adopted a neuronal fate stayed constant across groups, suggesting the drug acts on the size of the proliferative pool rather than on cell fate decisions themselves.

Three-dimensional reconstructions of individual immature neurons deepened the contrast. In male SAMP8 mice, the dendritic trees of doublecortin-positive cells were stunted: total dendritic length, dendritic surface area, segment counts, and terminal branch numbers were all reduced relative to controls, and Sholl analysis revealed fewer intersections at 60 to 70 micrometers from the cell body. ER272 reversed every one of these morphological deficits in males. Female SAMP8 mice displayed none of these abnormalities to begin with, and the treatment had no measurable effect on their neuronal architecture. In parallel, the team documented a four-fold surge in newly generated astrocytes—S100β-positive cells born during the treatment window—in male SAMP8 mice, reflecting the age-related shift of neural stem cells toward glial rather than neuronal commitment. The drug blocked that surge in males; females, whose astrocyte numbers were roughly half those of males throughout, showed no such shift and no drug response.

Analysis of the stem cell reservoir itself completed the picture. Both sexes of SAMP8 mice carried a reduced pool of radial glia-like neural stem cells, marked by GFAP and SOX2 expression. But when the researchers used MCM2, a component of the DNA replication licensing machinery, to identify stem cells that had re-entered the cell cycle, a sex split emerged: male SAMP8 mice showed a doubled proportion of activated stem cells, which treatment pushed to three times control levels, while females showed no change. The authors suggest that males may retain a larger reserve of resting, non-dormant stem cells capable of re-entering the cell cycle when stimulated, whereas females may simply have less baseline neurogenic activity to modulate—or may be at a different stage of pathological progression at six months of age.

Perhaps the most consequential finding concerns how the data are aggregated. When the researchers pooled males and females, the combined results closely mirrored the male phenotype across nearly every measure—new neurons, mature neurons, astrocytes, stem cell activation, and cognition—effectively erasing the female-specific patterns entirely. This male-driven bias in mixed-sex analyses has been documented in other preclinical fields, but seeing it play out across an entire neurogenic aging study is a stark demonstration of why the practice persists as a blind spot. Had the team analyzed only combined cohorts, the female data would have been invisible, and the conclusion would have been that the drug works uniformly.

The authors caution that several questions remain open. The estrous cycle was not monitored, though the two-month treatment spanned multiple cycles, making transient hormonal fluctuations an unlikely driver of the directional differences observed. Biodistribution of intranasally delivered ER272 was not directly tracked, so whether the compound acts directly on the hippocampus or through broader central signaling remains unresolved, and pulse-chase designs will be needed to separate effects on proliferation, survival, and lineage progression. Sex hormones, particularly estrogens, are known to modulate stem cell proliferation and neuronal survival and may contribute to the divergent trajectories. What the study establishes firmly is that male and female brains do not simply age at different speeds along a single path—they appear to follow distinct neurogenic aging trajectories altogether. For a field racing to develop therapies that boost adult neurogenesis against dementia, that distinction may determine which patients a treatment can actually help.

Subject of Research: Sex differences in hippocampal neurogenesis and cognitive response to diterpene treatment in a mouse model of accelerated aging

Article Title: Sex‐Specific Neurogenic and Cognitive Responses in a Murine Model of Accelerated Aging

Article References: Gómez‐Oliva, R., Chamorro‐Francisco, A., Atienza‐Navarro, I., Carrascal, L., Freire‐Aragón, M. D., Hernández‐Galán, R., Nunez‐Abades, P., García‐Alloza, M., & Castro, C. (2026). Sex‐Specific Neurogenic and Cognitive Responses in a Murine Model of Accelerated Aging. Aging Cell, 25(10), Article e70663. https://doi.org/10.1111/acel.70663

Image Credits: AI Generated

DOI: 10.1111/acel.70663

Keywords: hippocampal neurogenesis, aging, SAMP8 mice, sex differences, ER272, dentate gyrus, neural stem cells, cognitive decline, astrocytes, Morris water maze, protein kinase C, Alzheimer's disease

The research team, led by Ali Reza Malayeri and Seyed Esmaeil Khoshnam, set out to test whether zingerone could counteract the effects of D-galactose, a sugar that has become a standard laboratory tool for modeling aging in animals. When administered in excessive amounts over long periods, D-galactose accumulates in tissues and triggers the formation of reactive oxygen species, advanced glycation end products, and widespread cellular damage. In the brain, this cascade mimics many hallmarks of natural aging, including impaired memory, weakened motor coordination, neuronal loss, and chronic inflammation, which is why the compound is so widely used in preclinical studies of neurodegeneration.

Male Wistar rats were divided into five experimental groups. A control group received only normal saline, while an aging model group received daily subcutaneous injections of D-galactose at a dose of 100 milligrams per kilogram for eight consecutive weeks. Three additional groups received the same D-galactose regimen alongside daily oral doses of zingerone at 5, 10, or 20 milligrams per kilogram delivered by gavage. This design allowed the researchers to examine both whether zingerone had an effect and whether that effect depended on the dose, a critical consideration for any compound being evaluated as a candidate therapeutic agent.

To capture the behavioral consequences of brain aging and any protective action of the compound, the investigators employed a battery of standard tests. The Morris water maze assessed spatial learning and memory by measuring how quickly rats could locate a hidden platform in a pool of opaque water, a task heavily dependent on hippocampal function. The passive avoidance task evaluated the retention of a learned aversive memory. The open field test measured spontaneous locomotor activity and anxiety-like behavior, while the rotarod test assessed balance, coordination, and motor endurance by tracking how long animals could remain on a rotating rod. Together, these assays provided a multidimensional picture of both cognitive and motor function across the experimental groups.

The behavioral results were striking. Rats subjected to D-galactose alone showed the expected pattern of decline: longer times to find the hidden platform, weaker retention of avoidance memories, reduced exploratory locomotion, and shorter latencies before falling from the rotarod. Zingerone treatment, however, significantly reversed these deficits. The compound enhanced cognitive and motor performance across the treatment groups, and the improvements followed a clear dose-response pattern, with the 20 milligrams per kilogram dose producing the strongest protective effects. In the treated animals, spatial memory was sharper, avoidance learning was more robust, and motor endurance was substantially better preserved than in the untreated aging model group.

Beneath these behavioral gains, the biochemical analysis revealed a concurrent restoration of the brain’s redox balance. The researchers examined the oxidative-antioxidative status of the hippocampus, the seahorse-shaped structure essential for forming new memories that is among the first regions affected by aging and neurodegenerative disease. Zingerone treatment reduced lipid peroxidation, the oxidative degradation of membrane lipids that serves as a hallmark of free radical damage, while bolstering the activity of endogenous antioxidant defenses. By replenishing the cellular machinery that neutralizes reactive oxygen species, the compound appears to have interrupted the self-amplifying cycle in which oxidative damage impairs mitochondria, which in turn generate more oxidants.

Equally important was the compound’s impact on neuroinflammation. Chronic activation of inflammatory signaling in the brain, involving pro-inflammatory cytokines and the microglial cells that act as the nervous system’s immune sentinels, is now recognized as a central driver of age-related neurodegeneration. The study found that zingerone significantly reduced inflammatory markers in the hippocampus, suggesting that its antioxidant action extends into the immunological domain. Correlation analyses confirmed a significant association between oxidative stress markers, inflammatory cytokines, and cognitive performance, tying the biochemical improvements directly to the behavioral outcomes and strengthening the causal interpretation that the compound’s protection operates through these two intertwined mechanisms.

Histopathological evaluation reinforced the biochemical and behavioral findings. Qualitative examination of the cortex and hippocampal tissue showed that D-galactose exposure produced visible structural damage to neurons, while zingerone treatment attenuated these changes in a dose-dependent fashion. The preservation of tissue architecture, combined with improved redox status, dampened inflammation, and restored behavior, paints a coherent picture of a compound that protects the aging brain at multiple levels simultaneously, from molecule to cell to whole-animal function.

Zingerone is no stranger to neuroprotective research. It is a smaller, less pungent degradation product of [6]-gingerol and [6]-shogaol, the principal pungent constituents of ginger, and forms when these compounds are heated during cooking. Previous preclinical studies have suggested that zingerone can protect against cognitive deficits in models of cadmium toxicity, status epilepticus, ischemic stroke, and experimental diabetes, and pharmacokinetic work has demonstrated its oral bioavailability in rodents. A recent systematic review of preclinical studies concluded that zingerone holds promise as a neuroprotective agent against cognitive disorders, and studies of ginger constituents have also shown that these small phenolic molecules can cross the blood-brain barrier, a crucial property for any compound intended to act on the central nervous system.

The authors caution that these findings come from a rodent model and that animal results do not automatically translate to humans. D-galactose-induced aging is a useful experimental proxy, but it recapitulates only some aspects of natural human aging, and the doses used in the study far exceed any amount obtainable from dietary ginger. Nonetheless, the study strengthens the rationale for investigating zingerone as a therapeutic or preventive agent for age-related neurobehavioral decline. As natural compounds with potent antioxidant and anti-inflammatory properties continue to attract attention as candidates for healthy aging interventions, this work provides detailed mechanistic evidence that a familiar spice-derived molecule can protect the hippocampus, preserve memory and movement, and potentially blunt the biochemical storm that drives the aging brain toward dysfunction.

Subject of Research: Neuroprotective effects of the ginger-derived compound zingerone in a D-galactose-induced rat model of brain aging

Article Title: Zingerone mitigates cognitive and motor impairments in a D-galactose-induced brain aging model: Role of oxidative stress and neuroinflammation

Article References: Zingerone mitigates cognitive and motor impairments in a D-galactose-induced brain aging model: Role of oxidative stress and neuroinflammation. (n.d.). https://doi.org/10.1007/s11033-026-12748-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12748-0

Keywords: zingerone, ginger, brain aging, D-galactose, oxidative stress, neuroinflammation, hippocampus, cognitive decline, Morris water maze, neuroprotection, antioxidants, Wistar rats

The stakes of this question extend far beyond the laboratory. Spatial cognition, the capacity to acquire, store, and retrieve information about environmental geometry and object location, depends on a distributed brain network anchored by the hippocampal formation, with entorhinal grid cells and hippocampal place cells jointly constructing the cognitive maps that guide navigation. At the cellular level, the formation and consolidation of spatial memories rely on long-term potentiation at Schaffer collateral synapses connecting the CA3 and CA1 fields of the hippocampus, a process governed by NMDA and AMPA receptor-mediated glutamatergic transmission and finely tuned by dopaminergic, noradrenergic, and serotonergic inputs. Cathinone, khat’s principal psychoactive alkaloid, is a beta-keto phenethylamine structurally related to amphetamine that promotes the release of dopamine and norepinephrine and blocks their reuptake. Because dopamine and norepinephrine dynamically regulate hippocampal synaptic plasticity, cathinone’s pharmacological profile provides direct mechanistic grounds for suspecting that chronic khat exposure could disrupt the very synaptic machinery that spatial memory requires.

Human studies have long hinted at trouble. Chronic khat users perform worse than khat-free controls on working memory and cognitive flexibility tasks, on verbal learning and delayed recall, and across broader domains including attention, motor speed, decision-making, and inhibitory control, and a meta-analysis has linked khat use to measurable memory impairment. These deficits carry real functional consequences: compromised occupational performance, impaired driving safety, and reduced academic achievement among the university students and young adults among whom use is common. Yet human data are notoriously difficult to interpret. Polysubstance use, small and non-representative samples, and uncontrolled dosing histories all muddy the causal picture, leaving open the question of whether khat itself, rather than lifestyle factors correlated with its use, drives the cognitive decline. Controlled rodent experiments, which permit precise manipulation of dose, duration, and exposure route while excluding such confounds, are therefore essential for establishing a reliable dose-response relationship, and it is precisely this synthesis that the new review delivers.

To build their evidence base, the authors conducted a structured literature search across PubMed, ResearchGate, Elsevier, EMBASE, and Web of Science, screening records according to PRISMA 2020 methodology with a search end date of May 25, 2025. From an initial pool of 504 records, the investigators winnowed the field to fourteen primary studies meeting strict inclusion criteria: use of Catha edulis extract, juice, or purified cathinone; an in-vivo rodent model; validated behavioral assessment of spatial cognition; and quantifiable outcomes. The behavioral paradigms represented were dominated by the Morris Water Maze, employed in nine studies, which measures both spatial learning through escape latency and path length during acquisition trials and spatial memory retention through time spent in the target quadrant during probe trials. Three studies used the Radial Arm Maze, which tracks spatial working and reference memory through arm-entry patterns, while the T-maze, Y-maze, and Novel Object Recognition task each appeared in smaller numbers. Study quality was assessed with the SYRCLE Risk of Bias tool, validated specifically for animal intervention studies.

The pattern that emerged across the fourteen studies is strikingly duration-dependent. Acute exposure, defined as a single dose ranging from 40 to 500 milligrams per kilogram, produced bidirectional effects that initially appeared to follow an inverted-U curve. At the low end, doses of 40 to 100 milligrams per kilogram modestly improved exploratory behavior and reduced first-trial water maze latency, but the review’s authors interpret these gains as arousal-mediated motivation rather than genuine memory enhancement. At 150 to 500 milligrams per kilogram, every study reported consistent deficits across maze paradigms, including increased path length and latency and reduced working memory scores, with no graded response within this range. The reviewers argue this pattern reflects a threshold effect rather than a true inverted-U relationship: once dopaminergic stimulation exceeds a critical level, it disrupts the NMDA receptor-dependent processes required for spatial encoding. Finer dose stratification within the low-to-moderate range will be needed to settle the question formally.

Repeated exposure told a darker story. Subacute dosing, at 40 to 360 milligrams per kilogram over five to seventeen days, was consistently associated with spatial learning deficits, though with task-specific nuances: at 40 milligrams per kilogram over ten days, CBA mice showed disrupted reversal learning and impaired reference memory in the water maze, while the same dose over a shorter five-day protocol spared learning but impaired memory retention. Subchronic exposure of 29 to 90 days produced the most robust impairment profiles across multiple paradigms, with 100 milligrams per kilogram driving increased thigmotaxis, reduced spontaneous alternation, and elevated error rates in later training phases, though one study at the same dose reported no significant deficits, a discrepancy the authors attribute to methodological heterogeneity. Chronic exposure beyond 90 days, examined in a single study of 36 rats given 100, 200, or 300 milligrams per kilogram for twelve weeks, caused persistent spatial learning and memory impairment: at the highest dose, rats took significantly longer and swam significantly farther to reach the hidden platform, and spent significantly less time in the target quadrant during the probe trial. Critically, no study in the entire evidence base incorporated a washout period, so whether these deficits reverse after cessation remains entirely unknown.

Beneath the behavioral findings lie several converging mechanistic pathways that the review outlines with technical precision. As an indirect monoaminergic agonist, cathinone elevates extracellular dopamine, norepinephrine, and serotonin, and supranormal dopaminergic signaling can disrupt NMDA receptor-dependent long-term potentiation at hippocampal CA3-CA1 synapses, the cellular substrate of spatial learning. Chronic exposure has additionally been linked to reduced brain-derived neurotrophic factor signaling through its tropomyosin receptor kinase B, impaired neurogenesis, and altered dendritic spine morphology in the hippocampus, changes that would structurally erode the synaptic architecture on which memory consolidation depends. Oxidative stress and microglial activation may compound the damage by releasing pro-inflammatory cytokines such as interleukin-1 beta and tumor necrosis factor alpha, further impairing glutamatergic transmission. The authors caution, however, that direct mechanistic evidence from khat-exposed animals remains scarce, and they call for future studies combining behavioral testing with electrophysiology and molecular assays of BDNF/TrkB signaling, phosphorylated CREB, neuroinflammation, and oxidative stress markers.

The review is equally candid about the weaknesses of the evidence it synthesizes. The risk-of-bias assessment revealed that 78.6 percent of studies were at high risk of performance and detection bias because outcome assessment was not blinded, a serious concern in behavioral research where experimenter expectations can subtly inflate treatment effects. Allocation concealment was unreported in all fourteen studies, and random housing was described in only two. The evidence base is also narrow: 78.6 percent of studies used Swiss albino mice, an outbred stock with high inter-individual genetic variability, and nearly two-thirds originated from Ethiopia, with locally sourced khat of variable cathinone content that may range from 0.1 to 1.2 percent of dry weight and degrades rapidly after harvest into the weaker alkaloids cathine and norephedrine. Without standardized extract preparation and chemical fingerprinting, the nominal dose-response relationships reported across studies may not be directly comparable. All studies also relied on forced oral dosing rather than voluntary consumption models that better mirror human chewing behavior.

Translation to human exposure adds further nuance. Using body surface area scaling, the reviewers estimated that the rodent doses of 40 to 500 milligrams per kilogram correspond to human equivalent doses of roughly 6.5 to 81 milligrams per kilogram, a range whose upper end substantially exceeds realistic exposure from habitual khat chewing, estimated at approximately 7 to 28 milligrams of cathinone equivalent per session in a 70-kilogram adult. This suggests the most severe impairment profiles may reflect supraphysiological exposure scenarios, while the lower-dose studies more faithfully model everyday use. The authors argue that the cumulative message nonetheless justifies practical action: incorporating khat-use history into clinical cognitive screening, targeted public health education for youth, and epidemiological surveillance in endemic regions. Their research agenda calls for standardized cathinone-equivalent dosing, washout and recovery cohorts to test reversibility, multi-strain and both-sex comparisons, voluntary self-administration models, and longitudinal human studies integrating neuropsychological assessment with neuroimaging and biomarkers. For a plant woven into the social and economic fabric of an entire region, the emerging picture is one of meaningful cognitive risk that science is only beginning to map.

Subject of Research: Preclinical effects of the stimulant plant Catha edulis on spatial learning and memory in rodent models

Article Title: A narrative review of preclinical evidence on the effects of Catha edulis on spatial cognition and memory in rodents

Article References: Bekri, K., & Abiye, A. A. (2026). A narrative review of preclinical evidence on the effects of Catha edulis on spatial cognition and memory in rodents. Discover Toxicology, 3(1), Article 21. https://doi.org/10.1007/s44339-026-00066-w

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00066-w

Keywords: Catha edulis, khat, cathinone, spatial memory, spatial cognition, Morris water maze, hippocampus, long-term potentiation, neurotoxicology, BDNF, rodent models, narrative review